Skip to main content

Advertisement

Log in

Treatment strategy in a patient showing borderline features between plasmablastic lymphoma and plasmablastic myeloma harboring a 17p deletion

Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Castillo JJ, Bibas M, Miranda RN (2015) The biology and treatment of plasmablastic lymphoma. Blood 125(15):2323–2330. https://doi.org/10.1182/blood-2014-10-567479

    Article  PubMed  CAS  Google Scholar 

  2. Vega F, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, Finch CJ, Vilchez RA, McGregor D, Jorgensen JL (2005) Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 18(6):806–815. https://doi.org/10.1038/modpathol.3800355

    Article  PubMed  Google Scholar 

  3. Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES (2010) Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol 23(7):991–999. https://doi.org/10.1038/modpathol.2010.72

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ahn JS, Okal R, Vos JA, Smolkin M, Kanate AS, Rosado FG (2017) Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma. J Clin Pathol. https://doi.org/10.1136/jclinpath-2016-204294

  5. Dittus C, Grover N, Ellsworth S, Tan X, Park SI (2018) Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. Leuk Lymphoma 59(9):2121–2127. https://doi.org/10.1080/10428194.2017.1416365

    Article  PubMed  CAS  Google Scholar 

  6. Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, Olszewski AJ, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M (2018) Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. https://doi.org/10.1111/bjh.15156

  7. Castillo JJ, Reagan JL, Sikov WM, Winer ES (2015) Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol 169(3):352–355. https://doi.org/10.1111/bjh.13300

    Article  PubMed  CAS  Google Scholar 

  8. Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien M-L, Royer B, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Fontan J, Voillat L, Demarquette H, Collet P, Rodon P, Sohn C, Lifermann F, Orsini-Piocelle F, Richez V, Mohty M, Macro M, Minvielle S, Moreau P, Leleu X, Facon T, Attal M, Avet-Loiseau H, Corre J (2019) Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol 37(19):1657–1665. https://doi.org/10.1200/jco.18.00776

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Funding

This study was funded by MEXT KAKENHI Grant Number 17K07142.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Satoshi Yoshihara.

Ethics declarations

Conflict of interest

Authors KY and SY have received a speaker honorarium from Jansen. Author IM declares that he has no conflict of interest. Author TI declares that he has no conflict of interest. Author SM declares that he has no conflict of interest. Author MO declares that he has no conflict of interest. Author YS declares that he has no conflict of interest. Author SH declares that he has no conflict of interest. Author YF declares that he has no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoshihara, K., Yoshihara, S., Matsuda, I. et al. Treatment strategy in a patient showing borderline features between plasmablastic lymphoma and plasmablastic myeloma harboring a 17p deletion. Ann Hematol 99, 1405–1407 (2020). https://doi.org/10.1007/s00277-020-03975-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-03975-x

Navigation